In the clinical treatment of patients with IBD, infliximab, a humanized chimeric anti-TNF-α antibody, has demonstrated efficacy in relieving clinical symptoms by concurrently downregulating the expression of MMP1, MMP3, and MMP9 in these patients [39]. Here, MMP9 is linked to inflammatory bowel disease.